AB-101
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- AB-101
- ab 101
- Ab-101
- AB-101
- ab101
- AB101
- insular
- Insular
- PEGYLATED (5 KDA PEG) HUMAN RECOMBINANT INSULIN
- pegylated 5 kda peg human recombinant insulin
- ChEMBL ID
- CHEMBL4297681
- FDA ingredient codes (UNII)
- EH13UJP078
- First in class
- No
- Orphan designation
- No
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005366
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005556
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008219
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0012105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0019124
- Highest recorded phase
- 1
- NCT04673617
- NCT05960240
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (6)
- AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
- Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
- Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
- Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
In development for (11)
- Chronic hepatitis B virus infection Phase 1
- Diffuse large B-cell lymphoma Phase 1
- Granulomatosis with polyangiitis Phase 1
- Hodgkins lymphoma Phase 2
- Lupus nephritis Phase 1
- Mature T-cell and NK-cell non-Hodgkin lymphoma Phase 2
- Microscopic polyangiitis Phase 1
- Non-Hodgkin lymphoma Phase 1
- Pemphigus vulgaris Phase 1
- Rheumatoid arthritis Phase 1
- Systemic lupus erythematosus Phase 1